Literature DB >> 15996932

Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Kyoo-Hyung Lee1, Seong-Jun Choi, Jung-Hee Lee, Jung-Shin Lee, Woo-Kun Kim, Kyu-Bo Lee, Sang-Kyun Sohn, Jong-Gwang Kim, Dong-Hwan Kim, Miee Seol, Young-Shin Lee, Je-Hwan Lee.   

Abstract

BACKGROUND AND OBJECTIVES: Current grading systems of acute graft-versus-host disease (GVHD) cannot effectively identify patients with poor prognosis at the onset of acute GVHD after allogeneic hematopoietic cell transplantation. DESIGN AND METHODS: In a retrospective analysis, we evaluated the prognostic value of various clinical parameters at the initiation of treatment in 83 patients who developed systemic treatment-requiring acute GVHD after allogeneic hematopoietic cell transplantation.
RESULTS: Forty-three of 83 patients (52%) experienced initial treatment failure (40 required secondary treatment due to lack of response and 3 died) and 43 (52%) experienced treatment success, defined as completion of treatment (initial and, if given, secondary) within 100 days. The GVHD-specific survival rate was 65.5%, with 27 deaths due to GVHD-related complications without relapse of underlying malignancies within 1 year. HLA-mismatched transplantation, visceral initiation, and peripheral blood lymphocytopenia ( pound100/mL) were independent variables predicting higher initial treatment failure (Odd ratios (OR)=12.225, 12.036, and 7.481, respectively). The above variables and initial acute GVHD grade III-IV vs. II were independent variables predicting shorter GVHD-specific survival (OR=0.322, 0.247, 0.340, and 0.385, respectively). High-risk disease status, visceral initiation, and hypoalbuminemia ( pound2.8 g/dL) were independent variables predicting lower treatment success (OR=0.221, 0.162, and 0.270, respectively). The predictive value of visceral initiation and lymphocytopenia for GVHD-specific survival was verified in an independent cohort of 58 patients. INTERPRETATION AND
CONCLUSIONS: Lymphocytopenia and hypoalbuminemia may be useful baseline prognostic factors for acute GVHD after allogeneic hematopoietic cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996932

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  15 in total

1.  Plasma biomarkers of lower gastrointestinal and liver acute GVHD.

Authors:  Andrew C Harris; James L M Ferrara; Thomas M Braun; Ernst Holler; Takanori Teshima; John E Levine; Sung W Choi; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Daniel R Couriel; Pavan Reddy; Sophie Paczesny
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

2.  Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.

Authors:  Bipin N Savani; Stephan Mielke; Katayoun Rezvani; Aldemar Montero; Agnes S Yong; Laura Wish; Jeannine Superata; Roger Kurlander; Anurag Singh; Richard Childs; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-24       Impact factor: 5.742

Review 3.  Acute graft-versus-host disease: a bench-to-bedside update.

Authors:  Shernan G Holtan; Marcelo Pasquini; Daniel J Weisdorf
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

4.  α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

Authors:  John M Magenau; Steven C Goldstein; Dan Peltier; Robert J Soiffer; Thomas Braun; Attaphol Pawarode; Mary M Riwes; Maggi Kennel; Joseph H Antin; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Brian L Parkin; Gregory A Yanik; Sung Won Choi; Eli C Lewis; Charles A Dinarello; John Koreth; Pavan Reddy
Journal:  Blood       Date:  2018-02-02       Impact factor: 22.113

5.  Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT.

Authors:  S Fuji; K Takano; T Mori; T Eto; S Taniguchi; K Ohashi; H Sakamaki; Y Morishima; K Kato; K Miyamura; R Suzuki; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2014-08-11       Impact factor: 5.483

6.  CT in the clinical and prognostic evaluation of acute graft-vs-host disease of the gastrointestinal tract.

Authors:  A Shimoni; U Rimon; M Hertz; R Yerushalmi; M Amitai; O Portnoy; L Guranda; A Nagler; S Apter
Journal:  Br J Radiol       Date:  2011-11-29       Impact factor: 3.039

7.  Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies.

Authors:  Katarina Le Blanc; A John Barrett; Marie Schaffer; Hans Hägglund; Per Ljungman; Olle Ringdén; Mats Remberger
Journal:  Biol Blood Marrow Transplant       Date:  2009-09       Impact factor: 5.742

8.  Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

Authors:  Jeannine S McCune; Paolo Vicini; David H Salinger; Paul V O'Donnell; Brenda M Sandmaier; Claudio Anasetti; Donald E Mager
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-06       Impact factor: 3.333

9.  Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients.

Authors:  Carrie L Kitko; Sophie Paczesny; Gregory Yanik; Thomas Braun; Dawn Jones; Joel Whitfield; Sung W Choi; Raymond J Hutchinson; James L M Ferrara; John E Levine
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

10.  Influence of lactate dehydrogenase and cyclosporine A level on the incidence of acute graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Moo-Kon Song; Joo-Seop Chung; Young-Mi Seol; Bo-Ran Kwon; Ho-Jin Shin; Young-Jin Choi; Goon-Jae Cho
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.